A | B | C | D | E | F | G | H | I | J | K | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | FULL TITLE | TOPIC | Reviewed: | KEY WORDS | Link | DISORDER | Type of doc | PDF? | Year | Authors | Published in | ||||||||||||||
2 | The activation of phosphatidylinositol 3-kinase by Ras | PI3K | NO | BASIC RESEARCH | https://www.sciencedirect.com/science/article/abs/pii/S0960982200001779 | NEITHER | RESEARCH | YES | 1994 | Kodaki T, Woscholski R, Hallberg B,…Parker P | Curr Biol. | ||||||||||||||
3 | Biochemical characterization of the free catalytic p110 alpha and the complexed heterodimeric p110 alpha.p85 alpha forms of the mammalian phosphatidylinositol 3-kinase | PI3K | NO | BIOCHEMISTRY | https://pubmed.ncbi.nlm.nih.gov/7929193/ | NEITHER | RESEARCH | YES | 1994 | Woscholski R, Dhand R, Fry MJ, Waterfield MD, Parker PJ | J Biol Chem | PHENOTYPE | |||||||||||||
4 | Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene | PI3K | NO | CLONING / IDENTIFICATION | https://pubmed.ncbi.nlm.nih.gov/7713498/ | NEITHER | RESEARCH | YES | 1994 | Volinia S, Hiles I, Ormondroyd E, et al | Genomics | ||||||||||||||
5 | The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors | PI3K | NO | DNA SYNTHESIS | https://pubmed.ncbi.nlm.nih.gov/8090789/ | NEITHER | REVIEW | YES | 1994 | Roche S, Koegl M, Courtneidge SA | Proc Natl Acad Sci U S A | ||||||||||||||
6 | A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction | PI3K | NO | BASIC RESEARCH | https://pubmed.ncbi.nlm.nih.gov/8749393/ | NEITHER | RESEARCH | YES | 1995 | MacDougall LK, Domin J, Waterfield MD | Curr Biol. | ||||||||||||||
7 | Modulation of the substrate specificity of the mammalian phosphatidylinositol 3-kinase by cholesterol sulfate and sulfatide | PI3K | NO | CHOLESTEROL SULFATE / SULFATIDE | https://pubmed.ncbi.nlm.nih.gov/7547877/ | NEITHER | RESEARCH | YES | 1995 | Woscholski R, Kodaki T, Palmer RH, Waterfield MD, Parker PJ | Biochemistry | ||||||||||||||
8 | Phosphatidylinositol 3-kinase is involved in TRE-dependent gene expression in response to arginine vasopressin | PI3K | NO | PI3K | https://www.sciencedirect.com/science/article/abs/pii/S0006291X85725685 | NEITHER | RESEARCH | YES | 1995 | Nishioka N, Akimoto K, Moriya S, et al | Biochem Biophys Res Commun | ||||||||||||||
9 | Constitutive activation of protein kinase B and phosphorylation of p47phox by a membrane-targeted phosphoinositide 3-kinase | PI3K | NO | BASIC RESEARCH | https://www.sciencedirect.com/science/article/pii/S0960982202707136 | NEITHER | RESEARCH | YES | 1996 | Didichenko SA, Tilton B, Hemmings BA, Ballmer-Hofer K, Thelen M | Curr Biol. | ||||||||||||||
10 | Cloning and mutagenesis of the p110 alpha subunit of human phosphoinositide 3'-hydroxykinase | PI3K | NO | BASIC RESEARCH | https://pubmed.ncbi.nlm.nih.gov/9043658/ | NEITHER | RESEARCH | YES | 1997 | Stirdivant SM, Ahern J, Conroy RR, et al | Bioorg Med Chem | ||||||||||||||
11 | Differential effects of constitutively active phosphatidylinositol 3-kinase on glucose transport, glycogen synthase activity, and DNA synthesis in 3T3-L1 adipocytes | PI3K | NO | ADIPOCYTES | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC231743/ | NEITHER | REVIEW | YES | 1997 | Frevert EU, Kahn BB | Mol Cell Biol | ||||||||||||||
12 | Identification of four novel human phosphoinositide 3-kinases defines a multi-isoform subfamily | PI3K | NO | NOVEL PI3K ISOFORMS | https://pubmed.ncbi.nlm.nih.gov/9196049/ | NEITHER | RESEARCH | YES | 1997 | Ho LK, Liu D, Rozycka M, Brown RA, Fry MJ | Biochem Biophys Res Commun | ||||||||||||||
13 | Poor fetal nutrition causes long-term changes in expression of insulin signaling components in adipocytes | PI3K | NO | INSULIN | https://pubmed.ncbi.nlm.nih.gov/9252478/ | NEITHER | RESEARCH | YES | 1997 | Ozanne SE, Nave BT, Wang CL, Shepherd PR, Prins J, Smith GD | Am J Physiol | ||||||||||||||
14 | Downregulated expression of the signaling molecules Nck, c-Crk, Grb2/Ash, PI 3-kinase p110 alpha and WRN during fibroblast aging in vitro | PI3K | NO | SIGNALING | https://pubmed.ncbi.nlm.nih.gov/9531977/ | NEITHER | RESEARCH | YES | 1998 | Matuoka K, Takenawa T | Biochim Biophys Acta | ||||||||||||||
15 | The p85 and p110 subunits of phosphatidylinositol 3-kinase-alpha are substrates, in vitro, for a constitutively associated protein tyrosine kinase in platelets | PI3K | NO | PLATELETS | https://ashpublications.org/blood/article/91/3/930/261098/The-p85-and-p110-Subunits-of-Phosphatidylinositol | NEITHER | RESEARCH | YES | 1998 | Geltz NR, Augustine JA | Blood | ||||||||||||||
16 | Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase-related receptors | PI3K | NO | GPCR | https://www.sciencedirect.com/science/article/abs/pii/S0009308499000201 | NEITHER | RESEARCH | YES | 1999 | Katada T, Kurosu H, Okada T, et al | Chem Phys Lipids | ||||||||||||||
17 | Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein | PI3K | NO | RUK PROTEIN | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC306608/ | NEITHER | RESEARCH | YES | 2000 | Gout I, Middleton G, Adu J, et al | Embo j | ||||||||||||||
18 | Phosphatidylinositol-3' kinase-dependent vesicle formation in macrophages in response to macrophage colony stimulating factor | PI3K | NO | VESICLE FORMATION | https://pubmed.ncbi.nlm.nih.gov/10633084/ | NEITHER | RESEARCH | YES | 2000 | Murray J, Wilson L, Kellie S | J Cell Sci | ||||||||||||||
19 | The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling | PI3K | NO | ISOFORMS | https://pubmed.ncbi.nlm.nih.gov/10633072/ | NEITHER | RESEARCH | YES | 2000 | Hooshmand-Rad R, Hájková L, Klint P, et al | J Cell Sci | ||||||||||||||
20 | Regulation of voltage-dependent calcium channels in rat sensory neurones involves a Ras-mitogen-activated protein kinase pathway | PI3K | NO | BIOCHEMISTRY | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270090/ | NEITHER | RESEARCH | YES | 2000 | Fitzgerald EM | J Physiol | ||||||||||||||
21 | Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities | PI3K | NO | CAFFEINE / THEOPHYLLINE | https://pubmed.ncbi.nlm.nih.gov/12145276/ | NEITHER | RESEARCH | YES | 2002 | Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR | J Biol Chem | ||||||||||||||
22 | Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt | PI3K | NO | BASIC RESEARCH | https://pubmed.ncbi.nlm.nih.gov/12704201/ | NEITHER | RESEARCH | YES | 2003 | Ballou L, Lin H-Y, Fan G, Jiang Y-P, Lin RZ | J Biol Chem | ||||||||||||||
23 | Platelet-derived growth factor-BB-mediated activation of Akt suppresses smooth muscle-specific gene expression through inhibition of mitogen-activated protein kinase and redistribution of serum response factor | PI3K | NO | AKT | https://pubmed.ncbi.nlm.nih.gov/12882977/ | NEITHER | RESEARCH | YES | 2003 | Kaplan-Albuquerque N, Garat C, Desseva C, Jones PL, Nemenoff RA | J Biol Chem | ||||||||||||||
24 | Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo | PI3K | NO | REGULATION | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC321424/ | NEITHER | RESEARCH | YES | 2004 | Foukas LC, Beeton CA, Jensen J, Phillips WA, Shepherd PR | Mol Cell Biol | ||||||||||||||
25 | Trophic signals acting via phosphatidylinositol-3 kinase are required for normal pre-implantation mouse embryo development. | PI3K | NO | DEVELOPMENT | https://pubmed.ncbi.nlm.nih.gov/15020683/ | NEITHER | RESEARCH | YES | 2004 | Lu DP, Chandrakanthan V, Cahana A, Ishii S, O'Neill C | J Cell Sci | ||||||||||||||
26 | Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways | PI3K | NO | HYPERINSULINEMIA | https://pubmed.ncbi.nlm.nih.gov/16565309/ | PROS | RESEARCH | YES | 2006 | Samuelsson AM, Bollano E, Mobini R, et al | Am J Physiol Heart Circ Physiol | ||||||||||||||
27 | Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression | PI3K | NO | ANGIOGENESIS | https://onlinelibrary.wiley.com/doi/abs/10.1002/jcp.20707 | NEITHER | RESEARCH | YES | 2006 | Xia C, Meng Q, Cao Z, Shi X, Jiang BH | J Cell Physiol | ||||||||||||||
28 | Cancer-specific mutations in phosphatidylinositol 3-kinase | PI3K | NO | CANCER | https://pubmed.ncbi.nlm.nih.gov/17561399/ | NEITHER | REVIEW | YES | 2007 | Vogt PK, Kang S, Elsliger MA, Gymnopoulos M | Trends Biochem Sci | ||||||||||||||
29 | Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins | PI3K | NO | REGULATION | https://pubmed.ncbi.nlm.nih.gov/17680774/ | NEITHER | REVIEW | YES | 2007 | Wang P, Kumar P, Wang C, Defea KA | Biochem J | ||||||||||||||
30 | Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. | PI3K | NO | MST1 / RANBP2 / EIF4G BIOMARKERS | https://pubmed.ncbi.nlm.nih.gov/17372272/ | NEITHER | RESEARCH | YES | 2007 | Renner O, Fominaya J, Alonso S, Blanco-Aparicio C, Leal JF, Carnero A | Carcinogenesis | ||||||||||||||
31 | Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients | PHENOTYPE | YES | LIPOMATOSIS | https://onlinelibrary.wiley.com/doi/abs/10.1002/ajmg.a.32023 | CLOVES | CASE REPORT | YES | 2007 | Julie CS, Joyce TT, Jiddeke MvdK, Fleur SvD, Lowry RB, Leslie GB | Am J Med Genet A | ||||||||||||||
32 | Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern | PI3K | NO | EPIDERMAL DEVI | https://pubmed.ncbi.nlm.nih.gov/17673550/ | NEITHER | RESEARCH | YES | 2007 | Hafner C, López-Knowles E, Luis NM, et al | Proc Natl Acad Sci U S A | ||||||||||||||
33 | Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer | PI3K | NO | OVARIAN CANCER | https://pubmed.ncbi.nlm.nih.gov/17377809/ | NEITHER | RESEARCH | YES | 2007 | Woenckhaus J, Steger K, Sturm K, Münstedt K, Franke FE, Fenic I | Virchows Arch | ||||||||||||||
34 | Activity of the p110-alpha subunit of phosphatidylinositol-3-kinase is required for activation of epithelial sodium transport | PI3K | NO | BASIC RESEARCH | https://pubmed.ncbi.nlm.nih.gov/18653476/ | NEITHER | RESEARCH | YES | 2008 | Wang J, Knight ZA, Fiedler D, Williams O, Shokat KM, Pearce D | Am J Physiol Renal Physiol | ||||||||||||||
35 | Class I PI3K in oncogenic cellular transformation | PI3K | NO | CANCER | https://pubmed.ncbi.nlm.nih.gov/18794883/ | NEITHER | RESEARCH | YES | 2008 | Zhao L, Vogt PK | Oncogene | ||||||||||||||
36 | Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE) syndrome: CNS malformations and seizures may be a component of this disorder | PHENOTYPE | YES | SEIZURES | https://onlinelibrary.wiley.com/doi/abs/10.1002/ajmg.a.32515 | CLOVES | CASE REPORT | YES | 2008 | Zoran SG, Velibor T, Aleksandra J, et al | Am J Med Genet A | ||||||||||||||
37 | Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha | PI3K | NO | DRUG RESISTANCE | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720137/ | NEITHER | RESEARCH | YES | 2008 | Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM | Cancer Cell | ||||||||||||||
38 | Drug discovery approaches targeting the PI3K/Akt pathway in cancer | PI3K | NO | TREATMENT / CANCER | https://pubmed.ncbi.nlm.nih.gov/18794885/ | NEITHER | REVIEW | YES | 2008 | Garcia-Echeverria C, Sellers WR | Oncogene | ||||||||||||||
39 | Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike | PI3K | NO | DRUG RESISTANCE | https://www.sciencedirect.com/science/article/pii/S1535610808002316 | NEITHER | RESEARCH | YES | 2008 | Vogt PK | Cancer Cell | ||||||||||||||
40 | Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | PI3K | NO | PIK3CA H1047R / PI3K INHIBITOR | https://pubmed.ncbi.nlm.nih.gov/19029981/ | NEITHER | RESEARCH | YES | 2008 | Engelman JA, Chen L, Tan X, et al | Nat Med | ||||||||||||||
41 | Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose | PI3K | NO | 2-DEOXYGLUCOSE | https://pubmed.ncbi.nlm.nih.gov/18247380/ | NEITHER | RESEARCH | YES | 2008 | Jiang W, Zhu Z, Thompson HJ | Mol Carcinog | ||||||||||||||
42 | NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations | PI3K | NEED TO REVIEW | NVP-BEZ235 / CANCER | https://pubmed.ncbi.nlm.nih.gov/18829560/ | NEITHER | RESEARCH | YES | 2008 | Serra V, Markman B, Scaltriti M, et al | Cancer Res. | ||||||||||||||
43 | PI3K pathway alterations in cancer: variations on a theme | PI3K | NO | CANCER | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398461/ | NEITHER | REVIEW | YES | 2008 | Yuan TL, Cantley LC | Oncogene | ||||||||||||||
44 | PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences | PI3K | NO | UTERINE CANCERS | https://pubmed.ncbi.nlm.nih.gov/18180098/ | NEITHER | CASE REPORT | YES | 2008 | Miyake T, Yoshino K, Enomoto T, et al | Cancer Lett | ||||||||||||||
45 | The regulation of selective and nonselective Na+ conductances in H441 human airway epithelial cells | PI3K | NO | BIOCHEMISTRY | https://pubmed.ncbi.nlm.nih.gov/18310228/ | NEITHER | RESEARCH | YES | 2008 | Brown SG, Gallacher M, Olver RE, Wilson SM | Am J Physiol Lung Cell Mol Physiol | ||||||||||||||
46 | Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome | PHENOTYPE | YES | STUDY OF 18 CLOVES | https://journals.lww.com/clindysmorphol/Abstract/2009/01000/Characterization_of_a_distinct_syndrome_that.1.aspx | CLOVES | CASE REPORT | YES | 2009 | Ahmad IA | Clin Dysmorphol | ||||||||||||||
47 | Involvement of the p110 alpha isoform of PI3K in early development of mouse embryos | PI3K | NO | MOUSE | https://pubmed.ncbi.nlm.nih.gov/18932194/ | NEITHER | RESEARCH | YES | 2009 | Xu XY, Zhang Z, Su WH, et al | Mol Reprod Dev | ||||||||||||||
48 | Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction | PI3K | NO | CARDIAC / CONTRACTILE DYSFUNCTION | https://pubmed.ncbi.nlm.nih.gov/19597047/ | NEITHER | RESEARCH | YES | 2009 | Lu Z, Jiang YP, Wang W, et al | Circulation | ||||||||||||||
49 | The misnomer "macrocephaly-cutis marmorata telangiectatica congenita syndrome": report of 12 new cases and support for revising the name to macrocephaly-capillary malformations. | PHENOTYPE | YES | MACROCEPHALY | https://pubmed.ncbi.nlm.nih.gov/19289759/ | PROS | CASE REPORT | YES | 2009 | Dakara Rucker W, Ilona JF, Seth JO, et al | JAMA Dermatol | ||||||||||||||
50 | Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytes | PI3K | NO | CELL SURVIVAL | https://pubmed.ncbi.nlm.nih.gov/19065634/ | NEITHER | RESEARCH | YES | 2009 | Espada J, Galaz S, Sanz-RodrÃguez F, et al | J Cell Physiol | ||||||||||||||
51 | Overgrowth conditions: a diagnostic and therapeutic conundrum | DIAGNOSIS | YES | PERSPECTIVE | https://pubmed.ncbi.nlm.nih.gov/19380062/ | PROS | REVIEW | YES | 2009 | Matthew JC, Amir T, Joseph U | Hand Clinics | ||||||||||||||
52 | PIK3CA alterations in Middle Eastern ovarian cancers | PI3K | NO | OVARIAN CANCER | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724395/ | NEITHER | REVIEW | YES | 2009 | Abubaker J, Bavi P, Al-Haqawi W, et al | Mol Cancer. | ||||||||||||||
53 | VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway | PI3K | NO | VEGF / CANCER | https://pubmed.ncbi.nlm.nih.gov/19337377/ | NEITHER | RESEARCH | YES | 2009 | Chen CH, Lai JM, Chou TY, et al | PLoS One | ||||||||||||||
54 | CLOVE syndrome with nevus unis lateris: report of a case | PHENOTYPE | YES | NEVUS UNIS LATERIS | https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1525-1470.2010.01149.x | CLOVES | CASE REPORT | YES | 2010 | Deepika H, Anju A | Pediatr Dermatol | ||||||||||||||
55 | CLOVES syndrome with thoracic and central phlebectasia: increased risk of pulmonary embolism | PHENOTYPE | YES | PHLEBECTASIA | https://europepmc.org/article/med/20537357 | CLOVES | CASE REPORT | YES | 2010 | Ahmad IA, Burrows PE, Edward YL, Daniel H, John BM, Steven JF | J Thoracis Cardiovascular Surgery | ||||||||||||||
56 | Epidermal nevi | PHENOTYPE | YES | Epidermal nevi | https://pubmed.ncbi.nlm.nih.gov/20888465/ | PROS | REVIEW | YES | 2010 | Heather AB-B, Kimberly DM | Pediatr Clinics NA | ||||||||||||||
57 | Evidence for a role for the p110-alpha isoform of PI3K in skeletal function | PI3K | NO | SKELETAL FUNCTION | https://pubmed.ncbi.nlm.nih.gov/19931507/ | NEITHER | RESEARCH | YES | 2010 | Grey A, Chaussade C, Empson V, et al | Biochem Biophys Res Commun | ||||||||||||||
58 | The group of epidermal nevus syndromes Part I. Well defined phenotypes | PHENOTYPE | YES | EPIDERMAL NEVUS SYNDROMES | https://pubmed.ncbi.nlm.nih.gov/20542174/ | PROS | REVIEW | YES | 2010 | Rudolf H | J Am Acad Dermatol | ||||||||||||||
59 | The group of epidermal nevus syndromes Part II. Less well defined phenotypes | PHENOTYPE | YES | EPIDERMAL NEVUS SYNDROMES | https://pubmed.ncbi.nlm.nih.gov/20542175/ | PROS | REVIEW | YES | 2010 | Rudolf H | J Am Acad Dermatol | ||||||||||||||
60 | Hemihyperplasia-multiple lipomatosis syndrome: an underdiagnosed entity in children with asymmetric overgrowth | PHENOTYPE | YES | LIPOMATOSIS | https://pubmed.ncbi.nlm.nih.gov/20105568/ | PROS | REVIEW | YES | 2010 | Ozlem B, Yasemin A, Aycan K, Ibrahim K | J Pediatr Surg | ||||||||||||||
61 | Hermann Friedberg's case report: an early description of CLOVES syndrome | PHENOTYPE | YES | FRIEDBERG | https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-0004.2010.01479.x | CLOVES | CASE REPORT | YES | 2010 | Ahmad IA, Thiex R, John BM | Clin Genet | ||||||||||||||
62 | Klippel-Trenaunay syndrome and spinal arteriovenous malformations: an erroneous association | PHENOTYPE | YES | KLIPPEL-TRENAUNAY | https://pubmed.ncbi.nlm.nih.gov/20651014/ | PROS | CASE REPORT | YES | 2010 | Ahmad IA, Orbach DB, John BM, et al | Am J Neuroradiology | ||||||||||||||
63 | Perinatal clinical and imaging features of CLOVES syndrome | DIAGNOSIS | YES | IMAGING | https://pubmed.ncbi.nlm.nih.gov/20155260/ | CLOVES | REVIEW | YES | 2010 | Fernandez-Pineda I, Fajardo M, Chaudry G, Alomari AI. | Pediatr Radiol | ||||||||||||||
64 | PI3K p110 alpha and p110 beta have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts | PI3K | NO | ISOFORMS | https://www.nature.com/articles/cdd2009150 | NEITHER | RESEARCH | YES | 2010 | Matheny RW, Jr., Adamo ML | Cell Death Differ | ||||||||||||||
65 | PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA | PI3K | NO | REGULATION | https://pubmed.ncbi.nlm.nih.gov/20237330/ | NEITHER | RESEARCH | YES | 2010 | Lin RC, Weeks KL, Gao XM, et al | Arterioscler Thromb Vasc Biol | ||||||||||||||
66 | Progressive overgrowth of the cerebriform connective tissue nevus in patients with Proteus syndrome | PHENOTYPE | YES | PROTEUS SYNDROME / CEREBRIFORM | https://pubmed.ncbi.nlm.nih.gov/20709429/ | PROS | CASE REPORT | YES | 2010 | Thomas MB, Julie CS, Leslie GB, Thomas D. | J Am Acad Dermatol | ||||||||||||||
67 | Syndromes with focal overgrowth in infancy: diagnostic approach and surgical treatment | DIAGNOSIS | YES | DIAGNOSTIC APPROACH | https://pubmed.ncbi.nlm.nih.gov/21446802/ | CLOVES | CASE REPORT | YES | 2010 | Ursula M, Silke A, Olivia L-S, Petra M, Wolfgang S | J Plast Surg Hand Surg | ||||||||||||||
68 | Ablation of PI3K p110-α prevents high-fat diet-induced liver steatosis | PI3K | NO | BASIC RESEARCH | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292322/ | NEITHER | RESEARCH | YES | 2011 | Mohar Chattopadhyay, Elzbieta S. Selinger, Lisa M. Ballou, Richard Z. Lin | DIABETES | ||||||||||||||
69 | Comments on the diagnosis and management of CLOVES syndrome | DIAGNOSIS | YES | PERSPECTIVE | https://pubmed.ncbi.nlm.nih.gov/21504461/ | CLOVES | REVIEW | YES | 2011 | Ahmad IA | Pediatr Dermatol | ||||||||||||||
70 | Complex spinal-paraspinal fast-flow lesions in CLOVES syndrome: analysis of clinical and imaging findings in 6 patients | PHENOTYPE | YES | IMAGING STUDY | http://www.ajnr.org/content/32/10/1812.long | CLOVES | CASE REPORT | YES | 2011 | Ahmad IA, Gulraiz C, Rodesch G, et al | Am J Neuroradiology | ||||||||||||||
71 | Diagnosis and management of extensive vascular malformations of the lower limb: part I. Clinical diagnosis | DIAGNOSIS | YES | LOWER LIMB | https://pubmed.ncbi.nlm.nih.gov/22000870/ | PROS | REVIEW | YES | 2011 | Pedro R, Leyre A, Antonio M-C | J Am Acad Dermatol | ||||||||||||||
72 | Direct effects of rapid-acting insulin analogues on insulin signaling in human pancreatic islets in vitro | PI3K | NO | INSULIN | https://pubmed.ncbi.nlm.nih.gov/21354844/ | NEITHER | RESEARCH | YES | 2011 | D'Aleo V, Mancarella R, Del Guerra S, et al | Diabetes Metab | ||||||||||||||
73 | Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition | PI3K | NO | ISOFORMS | https://pubmed.ncbi.nlm.nih.gov/21778304/ | NEITHER | RESEARCH | YES | 2011 | Zheng Z, Amran SI, Thompson PE, Jennings IG | Mol Pharmacol | ||||||||||||||
74 | A proposal for classification of entities combining vascular malformations and deregulated growth | DIAGNOSIS | YES | PROS CLASSIFICATION | https://pubmed.ncbi.nlm.nih.gov/21356335/ | PROS | REVIEW | YES | 2011 | Charlène EUO, Chantal MAMvdH, Smitt JHS, et al | Embo j | ||||||||||||||
75 | Connective tissue nevi in children: institutional experience and review | PHENOTYPE | YES | CONNECTIVE TISSUE NEVI | https://pubmed.ncbi.nlm.nih.gov/22739355/ | PROS | CASE REPORT | YES | 2012 | Catherine CM, Caridad V, Victor K, et al | J Am Acad Dermatol | ||||||||||||||
76 | Development and evaluation of PIK75 nanosuspension, a phosphatidylinositol-3-kinase inhibitor | PI3K | NO | PI3K INHIBITOR | https://www.sciencedirect.com/science/article/abs/pii/S0928098712003673 | NEITHER | RESEARCH | YES | 2012 | Talekar M, Kendall J, Denny W, Jamieson S, Garg S | Eur J Pharm Sci. | ||||||||||||||
77 | Isolated macrodystrophia lipomatosa of the foot in a neonate: a case report | PHENOTYPE | YES | LIPOMATOSIS | https://pubmed.ncbi.nlm.nih.gov/21959860/ | PROS | CASE REPORT | YES | 2012 | Guzoglu N, Gokmen T, Oguz SS, Fitoz S, Dilmen U | Clin Dysmorphol | ||||||||||||||
78 | Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas | PI3K | NO | ADENOCARCINOMA | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854320/ | NEITHER | REVIEW | YES | 2012 | Murat CB, Braga PB, Fortes MA, Bronstein MD, Corrêa-Giannella ML, Giorgi RR | Braz J Med Biol Res | ||||||||||||||
79 | The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells | PI3K | NO | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645353/ | NEITHER | RESEARCH | YES | 2012 | Johnson AJ, Yeh YY, Smith LL, et al | Leukemia | |||||||||||||||
80 | Phenotypic progression of skeletal anomalies in CLOVES syndrome | PHENOTYPE | YES | SKELETAL ANOMALIES | https://onlinelibrary.wiley.com/doi/abs/10.1002/ajmg.a.35383 | CLOVES | CASE REPORT | YES | 2012 | Klein S, Stroberg A, Ghahremani S, Martinez-Agosto JA | Am J Med Genet A | ||||||||||||||
81 | Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome | PHENOTYPE | YES | MOSAIC MUTATIONS | https://www.cell.com/ajhg/fulltext/S0002-9297(12)00262-5 | CLOVES | CASE REPORT | YES | 2012 | Kurek KC, Luks VL, Ayturk UM, et al | Am J Hum Genet | ||||||||||||||
82 | CLOVES syndrome | PHENOTYPE | YES | CLINICAL PHENOTYPES | https://linkinghub.elsevier.com/retrieve/pii/S0363-5023(13)01188-X | CLOVES | REVIEW | YES | 2013 | Jacob B, Joseph U | J Hand Surg | ||||||||||||||
83 | Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy. | PI3K | NO | PI3K INHIBITOR | https://pubmed.ncbi.nlm.nih.gov/23632263/ | NEITHER | RESEARCH | YES | 2013 | Talekar M, Ganta S, Amiji M, et al | Int J Pharm | ||||||||||||||
84 | Lymphatic vessel abnormalities arising from disorders of Ras signal transduction | PHENOTYPE | YES | RAS | https://pubmed.ncbi.nlm.nih.gov/24183794/ | PROS | REVIEW | YES | 2013 | Eva MS-M, Philip DK | Trends Cardiovasc Med | ||||||||||||||
85 | New findings in genodermatoses | PHENOTYPE | YES | GENODERMATOSES | https://www.sciencedirect.com/science/article/abs/pii/S0733863512001714?via%3Dihub | CLOVES | REVIEW | YES | 2013 | Jonathan AD | Dermatol Clin | ||||||||||||||
86 | PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition | PI3K | NO | INHIBITOR | https://pubmed.ncbi.nlm.nih.gov/23439433/ | NEITHER | RESEARCH | YES | 2013 | Conte E, Gili E, Fruciano M, et al | Lab Invest. | ||||||||||||||
87 | PIK3CA-Related Segmental Overgrowth | PHENOTYPE | YES | OVERVIEW | https://pubmed.ncbi.nlm.nih.gov/23946963/ | PROS | REVIEW | YES | 2013 | Mirzaa G, Conway R, Graham JM, Jr., Dobyns WB | GeneReviews(®). Seattle (WA): University of Washington, Seattle | ||||||||||||||
88 | Reconstructive surgery in the management of a patient with CLOVES syndrome | TREATMENT | YES | RECONSTRUCTIVE SURGERY | https://pubmed.ncbi.nlm.nih.gov/23867238/ | CLOVES | CASE REPORT | YES | 2013 | Ballieux F, Modarressi A, Hammer F, et al | J Plast Reconstr Aesthet Surg | ||||||||||||||
89 | Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly | PHENOTYPE | YES | MACRODACTYLY | https://pubmed.ncbi.nlm.nih.gov/23100325/ | PROS | CASE REPORT | YES | 2013 | Rios JJ, Paria N, Burns DK, et al | Hum Mol Genet. | ||||||||||||||
90 | Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer | PI3K | NO | INHIBITOR / CANCER | https://pubmed.ncbi.nlm.nih.gov/23172887/ | NEITHER | RESEARCH | YES | 2013 | Wojtalla A, Fischer B, Kotelevets N, et al. | Clin Cancer Res | ||||||||||||||
91 | Activating PIK3CA somatic mutation in congenital unilateral isolated muscle overgrowth of the upper extremity | PI3K | NO | BASIC RESEARCH | https://pubmed.ncbi.nlm.nih.gov/24975390/ | NEITHER | RESEARCH | YES | 2014 | Castiglioni C, Bertini E, … Alvarez K | Am J Hum Genet | ||||||||||||||
92 | Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum | PHENOTYPE | YES | DELINIATION OF PROS | https://pubmed.ncbi.nlm.nih.gov/24782230/ | PROS | RESEARCH | YES | 2014 | Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al | Am J Med Genet A | ||||||||||||||
93 | Cloves syndrome: a case report and perinatal diagnostic findings | DIAGNOSIS | YES | PERINATAL | https://pubmed.ncbi.nlm.nih.gov/25365848/ | CLOVES | CASE REPORT | YES | 2014 | Puvabanditsin S, Memon N, Chekmareva M, Di Stefano V, Mehta R | Genet Couns | ||||||||||||||
94 | CLOVES syndrome: a malformational syndrome closely resembling Proteus syndrome | PHENOTYPE | YES | CLOVES OVERVIEW | https://pubmed.ncbi.nlm.nih.gov/25209813/ | CLOVES | CASE REPORT | YES | 2014 | Guillet A, Aubert H, Tessier MH, et al | Ann Dermatol Venereol | ||||||||||||||
95 | The diverse genetic landscape of neurodevelopmental disorders | PHENOTYPE | YES | NEURODEVELOPMENT | https://pubmed.ncbi.nlm.nih.gov/25184530/ | PROS | REVIEW | YES | 2014 | Wen FH, Maria HC, Christopher AW | Ann Rev Genom Human Genet | ||||||||||||||
96 | Management of visceral vascular anomalies | TREATMENT | YES | VASCULAR MALFORMATIONS | https://pubmed.ncbi.nlm.nih.gov/25241101/ | PROS | REVIEW | YES | 2014 | Dasgupta R, Fishman SJ | Semin Pediatr Surg | ||||||||||||||
97 | Megalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations | DIAGNOSIS | YES | EXOME SEQUENCING | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908952/ | CLOVES | RESEARCH | YES | 2014 | William JT, Nicola F, Nicholas CPC, et al | PLoS One | ||||||||||||||
98 | A Neonate with CLOVES Syndrome | PHENOTYPE | YES | NEONATE | https://www.hindawi.com/journals/cripe/2014/845074/ | CLOVES | CASE REPORT | YES | 2014 | Sarici D, Akin MA, Kurtoglu S, Tubas F, Sarici SU | Case Rep Pediatr. | ||||||||||||||
99 | The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma | PI3K | NO | MULTIPLE MYELOMA | https://www.nature.com/articles/onc2012594 | NEITHER | RESEARCH | YES | 2014 | Munugalavadla V, Mariathasan S, Slaga D, et al. | Oncogene | ||||||||||||||
100 | PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2 | PI3K | NO | CELL SURVIVAL | https://pubmed.ncbi.nlm.nih.gov/24645666/ | NEITHER | RESEARCH | YES | 2014 | Wahane SD, Hellbach N, Prentzell MT, et al | J Neurochem |